PMID- 35908834
OWN - NLM
STAT- MEDLINE
DCOM- 20220802
LR  - 20220923
IS  - 2056-5933 (Electronic)
IS  - 2056-5933 (Linking)
VI  - 8
IP  - 2
DP  - 2022 Jul
TI  - SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and 
      musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from 
      the EULAR COVAX physician-reported registry.
LID - 10.1136/rmdopen-2022-002322 [doi]
LID - e002322
AB  - BACKGROUND: There is a lack of data on SARS-CoV-2 vaccination safety in children 
      and young people (CYP) with rheumatic and musculoskeletal diseases (RMDs). 
      Current vaccination guidance is based on data from adults with RMDs or CYP 
      without RMDs. OBJECTIVES: To describe the safety of SARS-COV-2 vaccination in 
      adolescents with inflammatory RMDs and adults with juvenile idiopathic arthritis 
      (JIA). METHODS: We described patient characteristics, flares and adverse events 
      (AEs) in adolescent cases under 18 with inflammatory RMDs and adult cases aged 18 
      or above with JIA submitted to the European Alliance of Associations for 
      Rheumatology COVAX registry. RESULTS: A total of 110 cases were reported to the 
      registry. Thirty-six adolescent cases were reported from four countries, most 
      with JIA (42%). Over half (56%) reported early reactogenic-like AEs. One mild 
      polyarthralgia flare and one serious AE of special interest (malaise) were 
      reported. No CYP reported SARS-CoV-2 infection postvaccination.Seventy-four adult 
      JIA cases were reported from 11 countries. Almost two-thirds (62%) reported early 
      reactogenic-like AEs and two flares were reported (mild polyarthralgia and 
      moderate uveitis). No serious AEs of special interest were reported among adults 
      with JIA. Three female patients aged 20-30 years were diagnosed with SARS-CoV-2 
      postvaccination; all fully recovered. CONCLUSIONS: This is an important 
      contribution to research on SARS-CoV-2 vaccine safety in adolescents with RMDs 
      and adults with JIA. It is important to note the low frequency of disease flares, 
      serious AEs and SARS-CoV-2 reinfection seen in both populations, although the 
      dataset is limited by its size.
CI  - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Lawson-Tovey, Saskia
AU  - Lawson-Tovey S
AUID- ORCID: 0000-0002-8611-162X
AD  - Centre for Genetics and Genomics Versus Arthritis, The University of Manchester, 
      Manchester, UK.
AD  - National Institute of Health Research Manchester Biomedical Research Centre, 
      Manchester University NHS Foundation Trust, Manchester, UK.
FAU - Machado, Pedro M
AU  - Machado PM
AUID- ORCID: 0000-0002-8411-7972
AD  - Centre for Rheumatology & Department of Neuromuscular Diseases, University 
      College London, London, UK.
AD  - National Institute for Health Research (NIHR) University College London Hospitals 
      Biomedical Research Centre, University College London Hospitals NHS Foundation 
      Trust, London, UK.
FAU - Strangfeld, Anja
AU  - Strangfeld A
AUID- ORCID: 0000-0002-6233-022X
AD  - Epidemiology Unit, German Rheumatism Research Center Berlin, Berlin, Germany.
FAU - Mateus, Elsa
AU  - Mateus E
AD  - Portuguese League Against Rheumatic Diseases (LPCDR), Lisbon, Portugal.
AD  - Standing Committee of People with Arthritis/Rheumatism in Europe (PARE), European 
      League Against Rheumatism, Zurich, Switzerland.
FAU - Gossec, Laure
AU  - Gossec L
AUID- ORCID: 0000-0002-4528-310X
AD  - INSERM, Institut Pierre Louis d'Epidemiologie et de Sante Publique, Sorbonne 
      Universite, Paris, France.
AD  - APHP, Rheumatology Department, Hopital Universitaire Pitie Salpetriere, Paris, 
      France.
FAU - Carmona, Loreto
AU  - Carmona L
AUID- ORCID: 0000-0002-4401-2551
AD  - Instituto de Salud Musculoesqueletica, Madrid, Spain.
FAU - Raffeiner, Bernd
AU  - Raffeiner B
AD  - Department of Rheumatology, Central Hospital of Bolzano, Bolzano, Italy.
FAU - Bulina, Inita
AU  - Bulina I
AD  - Rheumatology Department, Paul Stradins Clinical University Hospital, Riga, 
      Latvia.
AD  - Riga Stradins University, Riga, Latvia.
FAU - Clemente, Daniel
AU  - Clemente D
AD  - Paediatric Rheumatology Department, Hospital Nino Jesus, Madrid, Spain.
FAU - Zepa, Julija
AU  - Zepa J
AD  - Riga Stradins University, Riga, Latvia.
AD  - Paul Stradins Clinical University Hospital, Riga, Latvia.
FAU - Rodrigues, Ana M
AU  - Rodrigues AM
AD  - Reuma.pt, Sociedade Portuguesa de Reumatologia, Lisboa, Portugal.
AD  - EpiDoC unit, CEDOC, Nova Medical School, Lisboa, Portugal.
FAU - Mariette, Xavier
AU  - Mariette X
AUID- ORCID: 0000-0002-4244-5417
AD  - Rheumatology, Universite Paris-Saclay, Assitance Publique-Hopitaux de Paris, 
      INSERM UMR1184, Hopital Bicetre, Le Kremlin-Bicetre, France.
FAU - Hyrich, Kimme L
AU  - Hyrich KL
AD  - National Institute of Health Research Manchester Biomedical Research Centre, 
      Manchester University NHS Foundation Trust, Manchester, UK 
      kimme.hyrich@manchester.ac.uk.
AD  - Centre for Epidemiology Versus Arthritis, The University of Manchester, 
      Manchester, UK.
CN  - EULAR COVAX
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - RMD Open
JT  - RMD open
JID - 101662038
RN  - 0 (COVID-19 Vaccines)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Arthralgia
MH  - *Arthritis, Juvenile/epidemiology
MH  - *COVID-19/epidemiology/prevention & control
MH  - *COVID-19 Vaccines/adverse effects
MH  - Child
MH  - Female
MH  - Humans
MH  - *Musculoskeletal Diseases/epidemiology/etiology
MH  - *Physicians
MH  - Registries
MH  - SARS-CoV-2
PMC - PMC9344592
OTO - NOTNLM
OT  - Arthritis, Juvenile
OT  - COVID-19
OT  - Vaccination
COIS- Competing interests: SL-T and BR have nothing to disclose. PMM reports 
      consulting/speaker's fees from Abbvie, BMS, Celgene, Eli Lilly, Galapagos, 
      Janssen, MSD, Novartis, Orphazyme, Pfizer, Roche and UCB, all unrelated to this 
      manuscript, and is supported by the National Institute for Health Research 
      (NIHR), University College London Hospitals (UCLH), Biomedical Research Centre 
      (BRC). AS reports personal fees from lectures for AbbVie, MSD, Roche, BMS, and 
      Pfizer. EM reports LPCDR received support for specific activities: grants from 
      Abbvie, Novartis, Janssen-Cilag, Lilly Portugal, Sanofi, Grunenthal S.A., MSD, 
      Celgene, Medac, Pharmakern, GAfPA; grants and non-financial support from Pfizer; 
      non-financial support from Grunenthal, outside the submitted work. LG reports 
      Amgen, Galapagos, Lilly, Pfizer, Sandoz; consulting fees: AbbVie, Amgen, BMS, 
      Celltrion, Galapagos, Gilead, GSK, Janssen, Lilly, Novartis, Pfizer, Samsung 
      Bioepis, Sanofi-Aventis, UCB, all unrelated to this manuscript. LC reports fees 
      or personal grants from any laboratory, but her institute works by contract for 
      laboratories among other institutions, such as Abbvie Spain, Eisai, Gebro Pharma, 
      Merck Sharp & Dohme Espana, S.A., Novartis Farmaceutica, Pfizer, Roche Farma, 
      Sanofi Aventis, Astellas Pharma, Actelion Pharmaceuticals Espana, Grunenthal, and 
      UCB Pharma. IB reports speaker fees from AbbVie, Pfizer, Janssen, Boehringer 
      Ingelheim, all unrelated to this manuscript. DC reports speakers fees from 
      Novartis, GSK, all unrelated to this manuscript. JZ reports speaker fees from 
      Abbvie, Novartis, Janssen/Johnson & Johnson, all unrelated to this manuscript. AR 
      reports research grants and consultant fees from Amgen and Pfizer, all unrelated 
      to this manuscript. KLH reports non-personal speaker's fees from Abbvie and grant 
      income from BMS, UCB, and Pfizer, all unrelated to this manuscript, and is 
      supported by the NIHR Manchester Biomedical Research Centre. XM is an Associate 
      Editor for this journal.
FIR - Stenova, Emoke
IR  - Stenova E
FIR - Dimitroulas, Theodoros
IR  - Dimitroulas T
FIR - Roux, Nicolas
IR  - Roux N
FIR - Durez, Patrick
IR  - Durez P
FIR - Leurs, Amelie
IR  - Leurs A
FIR - Carbone, Anna
IR  - Carbone A
FIR - Hachulla, Eric
IR  - Hachulla E
FIR - Toussirot, Eric
IR  - Toussirot E
FIR - Yardimci, Gozde Kubra
IR  - Yardimci GK
FIR - Puerta, Jose Ag
IR  - Puerta JA
FIR - Rubio, Natalia de la Torre
IR  - Rubio NT
FIR - Masaryk, Pavol
IR  - Masaryk P
FIR - Queyrel, Viviane
IR  - Queyrel V
FIR - Jeffrey, Rachel
IR  - Jeffrey R
FIR - Seror, Raphaele
IR  - Seror R
FIR - Floyd, Sharon
IR  - Floyd S
FIR - Rednic, Simona
IR  - Rednic S
FIR - Strakova, Eva
IR  - Strakova E
FIR - Kalyoncu, Umut
IR  - Kalyoncu U
FIR - Mylnarikova, Vanda
IR  - Mylnarikova V
EDAT- 2022/08/01 06:00
MHDA- 2022/08/03 06:00
PMCR- 2022/07/29
CRDT- 2022/07/31 21:04
PHST- 2022/03/08 00:00 [received]
PHST- 2022/07/15 00:00 [accepted]
PHST- 2022/07/31 21:04 [entrez]
PHST- 2022/08/01 06:00 [pubmed]
PHST- 2022/08/03 06:00 [medline]
PHST- 2022/07/29 00:00 [pmc-release]
AID - rmdopen-2022-002322 [pii]
AID - 10.1136/rmdopen-2022-002322 [doi]
PST - ppublish
SO  - RMD Open. 2022 Jul;8(2):e002322. doi: 10.1136/rmdopen-2022-002322.